rtam

Zilovertamab (UC-961) is a humanized anti-ROR1 monoclonal antibody that cuts off the WNT5A-induced ROR1 signaling pathway and shows anti-proliferative activity in ovarian and endometrial cancer cells. It can be used to study lymphatic cancer.

Ripertamab (SCT400), a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody (mAb), has applications in the research of hematological malignancies, particularly non-Hodgkin’s lymphoma (NHL) [1].

Ginisortamab (UCB6114), a fully human IgG4P monoclonal antibody targeting Gremlin-1, shows potential for investigating gastrointestinal (GI) tumors [1].

Omburtamab is a monoclonal antibody targeting CD276, often conjugated to 131 radioactive iodine ions, used for radioimmuno positron emission tomography studies.

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

Birtamimab (NEOD001) is a monoclonal antibody under investigation for its ability to selectively target and eliminate amyloid in the treatment of light chain amyloidosis [1].

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate composed of the humanized monoclonal antibody zilovertamab linked to the anti-microtubule cytotoxin monomethyl auristatin E (MMAE). Upon binding to ROR1 on tumor cells, it is rapidly internalized and directed to lysosomes for cleavage, releasing MMAE and inducing apoptosis in targeted cells. Zilovertamab vedotin has potential applications in cancer research [1].